title: Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.
abstract: The prognosis of relapsed acute myeloid leukemia (AML) in elderly patients is dismal, even if the AML exhibits a good prognostic karyotype, such as inv(16)(p13.1q22). We present a 72-year-old female with AML with inv(16)(p13.1q22) who suffered five episodes of relapse with temporary complete remission. Maintenance chemotherapy with oral cytarabine ocfosfate hydrate eventually produced persistent molecular complete remission of her AML that had not been induced by conventional regimens including intensive chemotherapy and low dose cytarabine therapy. The high level of tolerability to oral cytarabine ocfosfate hydrate may offer elderly patients with this type of AML a good chance for a cure.
authors: Department of Internal Medicine, Nanto Municipal Hospital, 938 Inami, Nanto, Toyama, 932-0211, Japan. rqxhf297@yahoo.co.jp.
authors: Masahisa
authors: M
authors: Arahata
authors: Department of Internal Medicine, Nanto Municipal Hospital, 938 Inami, Nanto, Toyama, 932-0211, Japan. rsf14240@nifty.com.
authors: Yukihiro
authors: Y
authors: Shimizu
authors: Department of Internal Medicine (III), Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. hasakura@staff.kanazawa-u.ac.jp.
authors: Hidesaku
authors: H
authors: Asakura
authors: Department of Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. snakao8205@staff.kanazawa-u.ac.jp.
authors: Shinji
authors: S
authors: Nakao
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000627:therapeutic use*; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics*; D003568:Cytidine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001088:Arabinonucleotides; C061162:1-arabinofuranosylcytosine-5'-stearylphosphate; D003568:Cytidine Monophosphate
references: J Natl Compr Canc Netw. 2012 Aug;10(8):984-1021
references: 22878824
references: Int J Hematol. 2012 Jul;96(1):84-93
references: 22639053
references: J Clin Oncol. 2005 Aug 20;23(24):5705-17
references: 16110030
references: Am J Blood Res. 2013 May 05;3(2):141-64
references: 23675565
references: J Clin Oncol. 2009 Oct 1;27(28):4747-53
references: 19720919
references: Haematologica. 2004 Aug;89(8):998-1008
references: 15339685
references: Blood. 2010 Jan 21;115(3):453-74
references: 19880497
references: Cancer. 2007 Mar 15;109(6):1114-24
references: 17315155
references: Blood. 2003 Jul 15;102(2):462-9
references: 12649129
references: Int J Hematol. 2008 Mar;87(2):118-25
references: 18228114
references: Cancer Res. 1994 Jan 1;54(1):109-13
references: 8261429
references: Br J Haematol. 2006 Nov;135(4):450-74
references: 17054678
references: Blood. 2009 Apr 30;113(18):4179-87
references: 19008455
references: Cancer. 2004 Jul 15;101(2):325-31
references: 15241830
references: Int J Hematol. 1997 Apr;65(3):263-8
references: 9114597